Skip to main content

Table 3 Timing of FEV1 decline and SGRQ deterioration in the overall population and GOLD subgroups

From: Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial

 

Overall

GOLD 2

GOLD 3

GOLD 4

Patients with both confirmed FEV1 decline and confirmed SGRQ deterioration, n (%)

1344 (100.0)

698 (100.0)

575 (100.0)

54 (100.0)

 On same assessment

240 (17.9)

121 (17.3)

108 (18.8)

9 (16.7)

 FEV1 decline before SGRQ deterioration

620 (46.1)

350 (50.1)

239 (41.6)

20 (37.0)

 SGRQ deterioration before FEV1 decline

484 (36.0)

227 (32.5)

228 (39.7)

25 (46.3)

 Moderate/severe exacerbation before FEV1 and SGRQ deterioration

546 (40.6)

246 (35.2)

269 (46.8)

24 (44.4)

Patients with confirmed FEV1 decline and no confirmed SGRQ deterioration, n (%)

1160 (100.0)

644 (100.0)

459 (100.0)

46 (100.0)

 Moderate/severe exacerbation before FEV1 decline

460 (39.7)

231 (35.9)

199 (43.4)

24 (52.2)

 Unconfirmed SGRQ deterioration

302 (26.0)

180 (28.0)

109 (23.7)

10 (21.7)

 On same assessment as confirmed FEV1 decline

34 (2.9)

20 (3.1)

12 (2.6)

1 (2.2)

 Before confirmed FEV1 decline

116 (10.0)

72 (11.2)

36 (7.8)

7 (15.2)

Patients with confirmed SGRQ and no confirmed FEV1 deterioration, n (%)

995 (100.0)

383 (100.0)

479 (100.0)

124 (100.0)

 Moderate/severe exacerbation before SGRQ deterioration

574 (57.7)

184 (48.0)

305 (63.7)

80 (64.5)

 Unconfirmed FEV1 deterioration

284 (28.5)

141 (36.8)

126 (26.3)

15 (12.1)

 On same assessment as confirmed SGRQ deterioration

50 (5.0)

23 (6.0)

24 (5.0)

3 (2.4)

 Before confirmed SGRQ deterioration

151 (15.2)

80 (20.9)

64 (13.4)

5 (4.0)

  1. Unscheduled visits were excluded for this analysis
  2. FEV1 forced expiratory volume in 1 s, GOLD Global Initiative for Chronic Obstructive Lung Disease, SGRQ St. George’s Respiratory Questionnaire